Mod GRF 1-29 (CJC-1295 no DAC) 5mg

Mod GRF 1-29 (CJC-1295 no DAC) 5mg

Mod GRF 1-29 (CJC-1295 no DAC) 5mg

Mod GRF 1-29 is a synthetic peptide identical to CJC-1295 without DAC compound. It is truncated analogue of growth hormone releasing hormone (GHRH), which was developed in 1980s from original GRF 1-29, but with purposefully prolonged half-life to ensure better therapeutical use. This modified version was shown to have similar or even the same effects as GHRH, including muscle and bone growth, wound healing, fat burning or positive effects on heart functions, metabolism or immune system.

In stock
€38.33
Quantity

ESTIMATED DELIVERY

Solution not bundled

PEPTIDE Appearance
Quantity:
2 mg
Unit:
1 Vial
Physical Appearance:
White powder
Salt form:
Acetate
Peptide Purity:
≥97%
Sequence:
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Molecular Mass:
3367.9
CAS NO.:
863288-34-0
Solubility:
Sterile / Bacteriostatic water 1ml/vial

Description of Mod GRF 1-29

Mod GRF 1-29 had its way of development. When it was discovered that the first 29 amino acids of growth hormone releasing hormone (GHRH) are of the equal potential as its full 44 amino acid structure, the shortest possible fragment called GRF 1-29 was developed. It was also called Sermorelin, but had a very short half-life, less than 10 minutes. To enhance biological activity and reduce rapid clearance, modified versions were synthesized. Analogues got substituted amino acids within the peptide structure with more resistant to enzymatic cleavage ones. So, the modified Mod GRF 1-29 with increased binding affinity to GHRH receptors and prolonged half-life was developed, too. Originally it was called tetrasubstituted GRF 1-29, but in 2008 a researcher in his work created term modified GRF 1-29 (Mod GRF 1-29). Let us discuss now, how the Mod GRF 1-29 went throughout different research studies.

Research Confirmed Effects

1. Mod GRF 1-29 and Gastrointestinal Effects

Researchers investigating growth hormone-releasing factor (GRF) analogues for potential therapeutic uses, such as in treating Crohn's disease and short bowel syndrome, found unexpected gastrointestinal (GI) side effects in monkeys. One potent analogue, caused severe diarrhea in monkeys during prolonged infusion, although it had no noticeable side effects in rats. Further analysis revealed that GRF-6 interacts with the vasoactive intestinal peptide receptor (VPAC1-R), suggesting this receptor is responsible for the diarrheal effects. Since VPAC1-R is found in the GI tract and affects smooth muscle activity, the interaction with this receptor could explain the increased and improved bowel motility in monkeys.

Another research exploring GRF and 14 GRF analogues' interactions with vasoactive intestinal peptide (VIP) receptors in rat pancreatic membranes found that some GRF analogues could inhibit VIP binding and activate adenylate cyclase. This interaction could suggest potential for side effects similar to those seen in monkeys, with GRF-6 causing severe diarrhea due to VPAC1-R interaction. The findings highlighted that alterations in specific positions within the peptide structure could markedly reduce receptor affinity and intrinsic activity, indicating how structural changes in GRF analogues could impact their receptor interactions and consequent side effects. The research underlines the complexity of receptor interactions with therapeutic peptides and the importance of carefully analyzing receptor activities in different species to avoid unwanted GI side effects.

[1] [2]

2. Mod GRF 1-29 in Diabetes and Heart Functions

Growth hormone-releasing hormone (GHRH) agonists, have been shown to have therapeutic potential beyond inducing pituitary growth hormone (GH) release. These agonists can promote cell proliferation and stimulate various tissues that express GHRH receptors (GHRH-Rs). Notably, GHRH agonists have demonstrated beneficial effects in pancreatic β-cell proliferation and metabolic function improvement, suggesting their utility in treating diabetes. Studies indicate that GHRH agonists can also enhance the engraftment of islets after transplantation, presenting a novel approach to diabetes therapy. Additionally, they have shown promise in repairing cardiac tissue, as evidenced by improved ejection fraction, reduction of infarct size, and attenuation of cardiac hypertrophy in rodent models. This points to potential applications in cardiac care, especially for heart attack recovery and heart failure treatment.

Beyond their impact on diabetes and heart health, GHRH agonists have demonstrated effects in other therapeutic areas. For instance, the presence of GHRH-Rs in ocular tissues and the neuroprotective effects of GHRH agonists in experimental diabetic retinopathy suggest possible therapeutic applications for eye diseases. GHRH agonists have also been found to accelerate wound healing, activate immune cells, and impact the central nervous system.

[3]

3. Mod GRF 1-29 and Growth Hormone Responses in Hypothyroidism

A common issue among individuals with hypothyroidism is the impaired release of growth hormone (GH). To better understand this, researchers conducted a study to evaluate the GH responses to growth hormone-releasing factor (GRF) in patients with primary hypothyroidism, both before and during thyroxine (T4) replacement therapy. The study involved fourteen patients, aged 26 to 60, who underwent GRF stimulation tests before and after T4 therapy (150 micrograms/day). The findings showed that thyroid hormone replacement therapy (T4) significantly enhanced GH responses to GRF in nine patients and in the group as a whole. Additionally, the area under the curve (AUC) measurements confirmed a general increase in GH response due to T4 therapy. These results suggest that T4 therapy enhances the responsiveness of somatotroph cells to GRF in patients with primary hypothyroidism.

The study provides valuable insights into the interaction between thyroid hormone and GH, indicating that thyroid hormone replacement therapy can positively influence GH responsiveness. This finding could help improve treatments for patients with hypothyroidism. However, when using modified GRF, some considerations need to be made regarding potential side effects, bioavailability, and dosage scaling. Although GRF exhibits moderate side effects, its bioavailability for subcutaneous administration is high, while its oral bioavailability is relatively low.

[4]

References

  1. T. Ito et al., “GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity,” Peptides, vol. 22, no. 7, pp. 1139–1151, Jul. 2001.
  2. M. Waelbroeck, P. Robberecht, D. H. Coy, J.-C. Camus, P. D. Neef, and J. Christophe, “Interaction of Growth Hormone-Releasing Factor (GRF) and 14 GRF Analogs with Vasoactive Intestinal Peptide (VIP) Receptors of Rat Pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(l-29)-NH2 as a VIP Antagonist,” Endocrinology, vol. 116, no. 6, pp. 2643–2649, Jun. 1985.
  3. A. V. Schally, X. Zhang, R. Cai, J. M. Hare, R. Granata, and M. Bartoli, “Actions and potential therapeutic applications of growth hormone-releasing hormone agonists,” Endocrinology.
  4. R. Valcavi et al., “Growth Hormone Responses to Grf 1–29 in Patients with Primary Hypothyroidism Before and During Replacement Therapy with Thyroxine,” Clin. Endocrinol. (Oxf.), vol. 24, no. 6, pp. 693–698, 1986.

Related products

Hexarelin 5mg
Hexarelin, also known as Examorelin, is a synthetic GH releasing hexapeptide, which activates growth hormone secretagogue receptor (GHSR) in the brain area. It is also ghrelin analog, similarly to other peptides such as GHRP-6. Beyond GH release and neuroendocrine effects, hexarelin might have also direct cardiovascular actions and cardioprotective...
  • In stock
€25.00
Ipamorelin 5mg
Ipamorelin represents a synthetic pentapeptide derived from GHRP-1, which has a very potent growth hormone (GH) releasing properties with efficacy and potency comparable to GHRP-6, both in vitro and in vivo. Unlike other GH secretagogues, ipamorelin very surprisingly does not induce a significant increase in adrenocorticotropic hormone (ACTH) or cortisol...
  • In stock
€22.50
GHRP-2 5mg
Peptide GHRP-2, also known as pralmorelin, is a synthetic hexapeptide, one of the first growth hormone secretagogues, that is known for its muscle growth increasing, ghrelin stimulating, immune system strengthening or sleep improving properties shown in numerous researches. GHRP-2 activates the release of growth hormone (GH) by binding to the growth...
  • In stock
€20.00
GHRP-6 5mg
Peptide GHRP-6, also known as growth hormone-releasing peptide 6, is a synthetic hexapeptide that specifically stimulates natural growth hormone release from the anterior pituitary gland by pituitary somatotrophs. It acts by binding to ghrelin receptors and mimics the effects of ghrelin – natural endogenous hormone. It has been researched for several...
  • In stock
€20.00
Mod GRF 1-29 (CJC-1295 no DAC) 5mg
Mod GRF 1-29 (CJC-1295 no DAC) 5mg
€38.33
Quantity